阿联酋首次对镰状细胞和地中海贫血进行CRISPR基因疗法,12月进行第一次治疗。 UAE launches first CRISPR gene therapy for sickle cell and thalassemia, with first treatment in December.

阿联酋在阿布扎比的亚斯诊所启动了第一个基于CRISPR/Cas9的基因疗法CASGEVY,用于治疗镰状细胞疾病和乙型地中海贫血,为12岁以上的病人核准。 The UAE has launched its first CRISPR/Cas9-based gene therapy, CASGEVY, at Yas Clinic in Abu Dhabi for sickle cell disease and beta thalassemia, approved for patients 12 and older. 这项治疗是与Vertex制药公司和阿布扎比Stem细胞中心共同开发的,涉及对病人的干细胞进行编辑,以便在重新注入之前纠正遗传缺陷。 The treatment, developed with Vertex Pharmaceuticals and the Abu Dhabi Stem Cells Centre, involves editing a patient’s stem cells to correct genetic defects before reinfusion. 第一次注入的时间定在12月初,与阿联酋国家日同时进行。 The first infusion is set for early December, timed with UAE National Day. 患者将通过保险和政府报销获得治疗。 Patients will access the therapy via insurance and government reimbursement. 该过程包括细胞收集、基因编辑、测试、注入和长期监测。 The process includes cell collection, gene editing, testing, infusion, and long-term monitoring. 该倡议标志着阿联酋保健进步迈出了一大步,减少了对海外治疗的需求,并使阿布扎比成为区域再生医学的领导者。 The initiative marks a major step in the UAE’s healthcare advancement, reducing the need for overseas treatment and establishing Abu Dhabi as a regional leader in regenerative medicine.